Muvr Labs, Inc. Labs Is Acquired by Exactech

The Muvr platform includes patient wearables, mobile device applications and chatbot texting, which allow surgeons to remotely monitor patient recovery.
Muvr

December 2, 2020

Muvr Labs Inc., a pioneer in intelligent patient wearables and digital communication tools, has been acquired by Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery.

The latest addition to Exactech’s Active Intelligence® platform of technologies, the Muvr portfolio is designed to help surgeons engage with their joint replacement patients throughout the journey of care.

The Muvr platform includes patient wearables, mobile device applications and chatbot texting, which allow surgeons to remotely monitor patient recovery. The wearable device continuously provides the healthcare team with real-time data on each patient’s experience and recovery. Wireless sensors worn by the patient measure the individual’s range of motion, not simply steps taken. The patent-protected, self-calibrating design allows the patient to manage the wearable independently without additional in-person office visits and requires minimal intervention by the healthcare team.

Muvr’s corresponding web application provides surgeons a dashboard to easily identify at-risk patients and connect remotely for follow-up. The surgeon/patient chatbot is a customizable software application that automatically conducts text conversations to provide patient reminders and respond to patients’ most common questions. The Muvr technology is designed to reduce the surgical team’s workload while collecting pain scores, exercise adherence, mobility metrics and survey information.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.